Medicare AdvantageCoverageMedium impact
MA08.113f, Enfortumab vedotin-ejfv (Padcev®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 2, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.113f for Enfortumab vedotin-ejfv (Padcev®) has been reissued with updates effective April 2, 2025. This is a pharmacy policy affecting coverage or authorization requirements for this oncology medication used primarily for bladder cancer treatment.
Action Required
By April 2, 2025: Review updated policy MA08.113f for Enfortumab vedotin-ejfv (Padcev®) at the provided URL to understand specific coverage or prior authorization changes for Medicare Advantage patients. Update billing workflows and prior authorization processes accordingly for this oncology medication.